The hairy cell leukemia market was valued at USD 130.7 million in 2023 and is projected to grow at a CAGR of 6.5% between 2024 and 2032 owing to increasing prevalence of leukemia.
Defining the role of epigenetic regulators in normal hematopoiesis has become critically important, as recurrent mutations or aberrant expression of these genes has been identified in both myeloid and
